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Poster Session-I 75statistically significant association between elevated CRP and
grades 0/1 versus grades 2–4 aGVHD (p5 0.1) or grades 0–2 versus
grades 3–4 aGVHD (p 5 0.21). Our data suggest that following
CRP values for the first seven days in patients undergoing HSCT
may identify patients more at risk for severe infections and eventual
transplant-related mortality.
Table 1
CRP Median UnivariateMultivariate
Variable Status N (Min/Max) p-value p-valueDiagnosis Malignant 50 4.37 (0.1/27.7) 0.03 0.16
Non-malignant 20 1.29 (0.31/24)Conditioning
RegimenMyeloablative 37 6.45 (0.39/24.6) 0.003 0.002Reduced Intensity 33 1.3 (0.1/27.7)
Donor Matched Sibling 32 3.8 (0.1/24.6) 0.26 –Alternative Donor 38 2 (0.21/27.7)
aGVHD Grades 0/I 52 2.75 (0.1/27.7) 0.1 –Grades II-IV 18 6.67 (0.32/24.6)
aGVHD Grades 0-II 60 3.15 (0.1/27.7) 0.21 –Grades III-IV 10 11.45 (0.32/23.2)
Severe
Infection
Yes 27 8.03 (0.1/27.7) 0.0005 0.0005No 43 1.64 (0.21/24.6)
Non-Relapse
Mortality
Yes 9 12.6 (0.77/27.7) 0.02 0.03No 61 2.44 (0.1/24.6)203
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To effectively compare center’s outcomes, patients (pts) need to be
risk-adjusted. Risk adjustment factors in pediatric and adult HSCT
are likely to be different. A risk score predictive of 1-year treat-
ment-related mortality (TRM) for pediatric pts undergoing alloge-
neic HSCT has been published (Matthes-Martin, BBMT, 2008
(14) p 335) using data fromGerman and Austrian centers. In this ret-
rospective analysis three factors were significant to predict the risk
for 1-year TRM: age . 10, alternative donor and advanced disease.
We evaluated several factors that could potentially affect the out-
come of allogeneic HSCT for pediatric pts. All pts undergoing allo-
geneic HSCT at Children’s Memorial Hospital from 2005–2007 (n
5 111) were evaluated. We retrospectively analyzed the following
variables: age, presence of malignancy, status of disease and high-
risk disease features such as cytogenetic or molecular markers, type
of conditioning (myeloablative vs. reduced intensity), use of TBI,
prior transplant, existence of co-morbidities, cell source , Matthes-
Martin score, and degree of HLA match between donor and recipi-
ent with respect to 100-day and 1-year survival using Fisher’s exact
test (see Table). In our cohort of patients, degree of match (8 of 8
vs.#7 of 8) was significantly related to 100 day (p 5 0.001) and 1
year (p 5 0.004) mortality. All other factors analyzed were not pre-
dictive of mortality. The Matthes-Martin score of $2 (n 5 26) ap-
proached significance with respect to 100 day mortality (p 5 0.06)
but was not predictive for 1-year mortality (p5 0.36). Potential dif-
ferences in our pts from the Matthes-Martin pts include: younger
median age (6.5 vs 8.7yrs), fewer malignancy pts (61 vs 72%), fewer
marrowHSC (12 vs 50%) andmore PBSC (67 vs 49%) in our cohort.
In conclusion, because of the diversity of patients in both cohorts we
could not validate theMatthes-Martin score for risk adjustedmortal-
ity in our center. Further analyses of larger cohorts of patients are re-
quired to evaluate this method. These characteristics in turn, need to
be validated at individual centers and over time as supportive care
evolves.Potential Risk Factors for Pediatric HSCT
1-year
Patient Characteristic N 100-day Mortality P value* mortality P value*All patients 111 15 (14%) 24 (22)
Malignancy 68 8 (12%) 15 (22%)
Non-malignancy 43 7 (16%) n.s. 9 (21%) n.s.
Myeloablative 49 6 (12%) 12 (24%)
Reduced Intensity 62 9 (15%) n.s. 12 (19%) n.s.
HSC Source: umbilical
cord blood
24 4 (17%) 6 (25%)HSC source: bone
marrow13 2 (15%) n.s. 4 (31%) n.s.HSC source: peripheral
blood stem cells74 9 (12%) n.s. 14 (19%) n.s.Maathes-Martin
score 0-185 8 (9%) 16 (19%)Maathes-Martin
score $226 7 (27%) p 5 0.06 8 (31%) p 5 0.36HLA* matched (8 of 8) 67 3 (4%) 8 (12%)
HLA* match #7 of 8 44 12 (27%) p 5 0.00116 (36%) p 5 0.004*P value calculated using Fisher Exact Test; HLA match at A, B, C and
DRb1 loci204
REDUCED INTENSITY CONDITIONING (RIC) ALLOGENEIC STEM CELL
TRANSPLANTATION (ALLOSCT) IN CHILDREN AND ADOLESCENT RECIP-
IENTS IS ASSOCIATED WITH VERY LOW REGIMEN RELATED AND NON-
RELAPSE MORTALITY (NRM): HOWEVER, CHEMONAIVE PATIENTS
FOLLOWING UMBILICAL CORD BLOOD TRANSPLANT (UCBT) HAVE A
HIGHER INCIDENCE OF PRIMARY GRAFT FAILURE (PGF)
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Myeloablative-AlloSCT is associated with a 20–40%NRM in the
first 100 days post AlloSCT. RIC may decrease this high mortality
but data in pediatric recipients is limited (Satwani/Cairo et al,
BBMT 2005; PBC 2007). We evaluated the feasibility and toxicity
of RI-AlloSCT in 83 children and adolescents with malignant (n 5
47) and non-malignant (n 5 36) disease: Median age 10 6 6.7yrs,
UCB (n5 42), matched family donor (MFD) (n5 32), matched un-
related donor (MUD) (n 5 9); average risk (n 5 72), poor risk (n 5
11). Busulfan (6.4–8mg/kg)1fludarabine (150–180mg/m2)6ATG
(8mg/m2) (n 5 45); cyclophospamide (60mg/kg)1fludarabine
(150mg/m2)6ATG (8mg/m2) (n 5 18); and busulfan (12.8–16mg/
kg)1fludarabine (150mg/m2)1alemtuzumab (54mg/ m2) (n 5 20).
Median follow-up is 951 6 776d. Median time to neutrophil and
plt recovery was 16 (CI95; 15,18) and 33 (CI95;30,48) days, respec-
tively. The probability of neutrophil and plt recovery was 96.1 6
2.2% and 83 6 4.3%, respectively. Median chimerism on day 30,
60, 100 and 365 was 95% vs 97% vs 98% and 99%, respectively.
The probability of aGVHD (Gr I-IV) was 30 6 5% in all pts and
15.4 6 5.7% in pts with UCB and 41.2%68.79% in MFD (p 5
.015). The probability of cGVHD was 20 6 5.3% in all pts and 10
6 5.7% in pts with UCB and 38.5%69.68% in MFD (p 5 .006).
The incidence of PGF was 13.8 6 3.86%. The incidence of PGF
in UCBT was 28.2 6 7.2% vs 0% in MFD or MUD (p 5 0.0014).
The incidence of PGF in UCBT chemo-naı¨ve pts was 50 6 11%
vs non-chemo naı¨ve was 5.3 6 5% (p 5 0.002). On univariate anal-
ysis for PGF, gender, regimen, disease risk status, CMV status, UCB
cell dose and HLA match did not reach statistical significance; age
(p5 0.19), non-malignant disease (p5 0.05) and chemo-naı¨ve status
(p5 0.03) reached statistical significance. However, in a multivariate
analysis age (p 5 0.2), non-malignant disease (p 5 0.8) and chemo-
naı¨ve status (p 5 0.06) did not achieve statistical significance. The
day 100 NRM was 3 6 2% and overall NRM was 14.7 6 4.5%.
The incidence of serious adverse events (gr III-IV) was 12.5%.
The 1 and 5yr OS for pts with malignant diseases was 71.1 6 6.7
